Mohankumar Kurukumbi, MD
Neurology · Alexandria, VANPI 1871752279
Payments from drug & device makers
Across 570 payments — averaging $112.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$45K
- Livanova USA, Inc.$9K
- Medtronic$2K
- SK Life Science, Inc.$2K
- Neuropace, Inc.$1K
- AbbVie$1K
- plus $5K from 31 others
What the payments were for
- Consulting fees$6,80011%
- Speaking & faculty fees$33,16752%
- Travel & lodging$7,84812%
- Food & beverage$16,53326%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 202 | $45,023 |
| Livanova USA, Inc. | 32 | $8,555 |
| Medtronic(2 entities) | 17 | $1,801 |
| SK Life Science, Inc. | 53 | $1,657 |
| Neuropace, Inc. | 10 | $1,158 |
| AbbVie(2 entities) | 62 | $1,010 |
| Sunovion Pharmaceuticals Inc. | 34 | $699 |
| Supernus Pharmaceuticals, Inc. | 28 | $595 |
| Jazz Pharmaceuticals Inc. | 8 | $572 |
| Neurelis, Inc. | 15 | $542 |
| Sumitomo Pharma America, Inc. | 25 | $462 |
| Lilly USA, LLC | 8 | $244 |
| Avanir Pharmaceuticals, Inc. | 6 | $221 |
| AstraZeneca | 6 | $217 |
| Catalyst Pharmaceuticals, Inc. | 3 | $203 |
| Teva Pharmaceuticals USA, Inc. | 6 | $143 |
| Eisai Inc. | 7 | $141 |
| Novartis | 7 | $121 |
| Zogenix Inc. | 2 | $118 |
| Sanofi | 4 | $95 |
| Amgen | 4 | $94 |
| Biogen | 5 | $93 |
| Corium, LLC | 4 | $89 |
| Aucta Pharmaceuticals, Inc. | 1 | $80 |
| Acorda Therapeutics, Inc | 4 | $73 |
| Lundbeck LLC | 2 | $55 |
| Harmony Biosciences LLC | 2 | $51 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| EMD Serono, Inc. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Avion Pharmaceuticals | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$20,499
- Briviact$15,013
- Nayzilam$4,764
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$3,386
- VNS Therapy$2,898
- VNS - Sentiva$1,609
- ACTIVA$1,041
- RNS Neurostimulator Kit$712
- PERCEPT PC BRAINSENSE$344
- VALTOCO$251
- Epidiolex$237
- RNS System$142
- NUEDEXTA$125
- SOLIRIS$116
- Fycompa$111
- XCOPRI$102
How this compares
$64,360 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 154 | $308,921 |
| Lacosamide | 552 | $117,826 |
| NayzilamMidazolam | 72 | $88,120 |
| EpidiolexCannabidiol (Cbd) | 31 | $84,898 |
| VimpatLacosamide | 28 | $76,361 |
| AptiomEslicarbazepine Acetate | 21 | $57,571 |
| XcopriCenobamate | 29 | $47,270 |
| Clobazam | 200 | $43,141 |
| KeppraLevetiracetam | 22 | $40,135 |
| TrileptalOxcarbazepine | 32 | $34,657 |
| Keppra XrLevetiracetam | 15 | $31,489 |
| FycompaPerampanel | 20 | $28,504 |
| Levetiracetam ErLevetiracetam | 240 | $25,807 |
| ValtocoDiazepam | 20 | $25,043 |
| Lamotrigine ErLamotrigine | 47 | $19,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam, Vimpat | $45,023 | $473,402254 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $699 | $57,57121 claims |
| SK Life Science, Inc.Xcopri | $1,657 | $47,27029 claims |
| Eisai Inc.Fycompa | $141 | $28,50420 claims |
| Neurelis, Inc.Valtoco | $542 | $25,04320 claims |
| Lilly USA, LLCOlanzapine | $244 | $53813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.
Other neurology in Alexandria
- Ramsey FalconerAlexandria$2.4M
- Simon FishmanAlexandria$1.6M
- John CochranAlexandria$79K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Robert ShinCharlottesville$2.2M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.